1. Introduction {#sec1}
===============

Monoclonal antibodies targeting programmed cell death 1 protein (PD-1) have shown to improve progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma \[[@B1]\]. The advent of anti-PD-1 antibodies along with antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and therapies targeting BRAF mutation has provided multiple options to treat patients with metastatic melanoma. Due to these therapies, the median overall survival of metastatic melanoma has improved from 6 months to more than 3 years \[[@B2]--[@B4]\]. Currently, two monoclonal antibodies targeted against PD-1 have been approved as first-line agents for the treatment of metastatic melanoma \[[@B1]\].

PD-1 inhibitors can lead to durable responses \[[@B1], [@B5]\] and have better toxicity profiles as compared to CTLA-4 inhibitors and targeted therapies \[[@B1], [@B3], [@B4]\]. However, approximately, 86% of patients experiencing treatment-related toxicities (all grades) and severe (grade 3 or higher) toxicities are in the range of 17 to 22% \[[@B3], [@B4]\]. Treatment discontinuation due to immune-related adverse events (irAEs) is estimated to occur in 15% to 25% of patients \[[@B3], [@B4]\]. These patients lack effective therapies as many of them do not have actionable mutation, and even in patients with BRAF mutation, the median PFS with BRAF-MEK inhibitors is low (11 to 15 months) with a high rate of toxicities \[[@B1], [@B6], [@B7]\]. Therefore, there is a need to understand the long-term prognosis of patients who undergo treatment discontinuation due to irAE to guide management decisions.

2. Materials and Methods {#sec2}
========================

After approval from the Institutional Review Board, data of 1264 patients enrolled at Melanoma Skin & Ocular Tissue Repositories at Holden Comprehensive Cancer Center at the University of Iowa Hospitals and Clinics from 8/1/2012 to 7/31/2017 was reviewed. Patients with unresectable, advanced, or metastatic cutaneous melanomas who discontinued anti-PD-1 therapies due to irAEs were identified and their charts were reviewed in detail. Reviewed data included demographics (gender, race, and ethnicity), mutational status, prior treatment regimens including radiation therapy, melanoma metastases to brain and liver, and irAEs. Identified patients were followed till 02/26/2019. Progression (clinical or radiological) and responses were determined by iRECIST \[[@B8]\] and clinic notes. Outcomes with anti-PD-1 therapies including PFS, time from treatment discontinuation to progression, and OS were collected. Common Terminology Criteria for Adverse Events Criteria Version 4.03 were used to grade irAE \[[@B9]\].

2.1. Statistical Analysis {#sec2.1}
-------------------------

Baseline clinical and disease characteristics were summarized as medians and ranges for continuous variables and as numbers and percentages for categorical variables. Kaplan-Meier survival analysis was used to determine PFS and OS. Time was calculated from initiation of anti-PD-1 treatment to progression or, new treatment for PFS, time from last treatment to next treatment or progression for clinical benefit and to death due to any cause for OS. Durable clinical benefit was defined as time of 6 months or more to progression or next treatment from last therapy. Survival curves were drawn using GraphPad Prism Version 7.04 (GraphPad Software, Inc., San Diego, CA).

3. Results {#sec3}
==========

3.1. Baseline Characteristics {#sec3.1}
-----------------------------

Overall 169 patients with advanced, unresectable, or metastatic cutaneous melanoma received anti-PD-1 therapy, of which 16 (9.5%) patients discontinued treatment due to irAEs. All patients who discontinued treatment were white and non-Hispanic. The median age was 64.5 (range 35 to 81) years. Ten (62.5%) patients were male and six (37.5%) were female. Eight (50%) patients had a BRAF mutation. Four (25%) patients had brain metastasis and one (6.3%) had liver metastasis. Six (37.5%) patients had prior treatment with ipilimumab for metastatic disease. [Table 1](#tab1){ref-type="table"} provides the baseline demographics and clinical profile of all patients.

3.2. Treatment {#sec3.2}
--------------

Fifteen (93.7%) patients received pembrolizumab and one (6.3%) patient received nivolumab. Eight (50%) received anti-PD-1 therapy as the first line, seven (43.7%) as second, and one (7.3%) as the third line. Patient 6 received bevacizumab in addition to pembrolizumab after 6 cycles of single-agent pembrolizumab due to pseudoprogression in the brain. None of the patients received concomitant radiation with anti-PD-1 therapy. The median duration of treatment was 4.7 (range 0.7 to 11.5) months. [Table 2](#tab2){ref-type="table"} provides a summary of treatment duration, line of therapy, and outcomes of each patient.

3.3. irAEs {#sec3.3}
----------

The median duration from initiation of treatment to development of irAE was 4 (range 0.5-11.5) months. Most commonly observed toxicities leading to treatment discontinuation included diarrhea and rash (4/16, 25% each) and arthritis (3/16, 18.7%). Other observed toxicities included colitis (2), neuropathy (2), pancreatitis (2), fatigue, nausea, nephritis, adrenal insufficiency, hypothyroidism, low mood, mouth sores, hepatitis, uveitis, and myasthenia flare (1 each). Ten (62.5%) patients experienced grade 3 or higher toxicities. [Table 3](#tab3){ref-type="table"} provides a summary of these toxicities and immunosuppressive agents used for their management. Apart from the mentioned toxicities, patient 1 developed grade 2 hypothyroidism on day 81 and patient 8 developed grade 2 pityriasis lichenoides after 2 cycles secondary to pembrolizumab. However, both did not lead to treatment discontinuation.

3.4. Outcomes {#sec3.4}
-------------

Median follow-up was 30.3 (range 4.6 to 49.4) months. Eight (50%) had complete response, five (31.2%) had partial response, two (12.5%) had stable disease, and one (6.3%) had progressive disease as best response to treatment. At the time of analysis, 8 patients had progressed and 4 patients experienced all-cause mortality, of which one death was unrelated to melanoma. Median PFS was 24.6 months and median OS was not reached due to durable disease control (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Durable clinical benefit was observed in 13 (81.2%) patients.

Patients number 4 and 16 had a PFS of less than 6 months PFS ([Figure 3](#fig3){ref-type="fig"}). Patient 4 had underlying thymoma and patient 16 had myasthenia gravis. With pembrolizumab, they experienced severe neuroimmune toxicity and flare-up of myasthenia gravis, respectively, which caused rapid clinical deterioration. All patients except one received steroids (oral, topical, or ophthalmic), while two received steroid-sparing agents. Of the eight patients who progressed, three were retreated with pembrolizumab-containing regimen. Of these three patients, one developed pembrolizumab induced psoriasis, while the remaining two tolerated it without any significant side effects ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

Prior studies have given conflicting evidence with regard to the association of PD-1-related irAEs with survival outcomes in melanoma patients. Freeman-Keller et al. reported OS association with rash and vitiligo, while no survival benefit was seen with other irAEs including endocrinopathies, colitis, or pneumonitis. In the study, 12-week landmark PFS analysis was difficult to interpret due to exclusion of a large number of patients \[[@B10]\]. Another pooled analysis of 576 patients by Weber et al. reported that after exclusion of patients progressing before 12 weeks, there was no difference in PFS between patients without AEs and those with one to two AEs or between those with any-grade AE and all patients \[[@B11]\]. In another study by Indini et al., irAE was associated with improved PFS \[HR 0.47 (95% CI 0.26, 0.86); p = 0.016\] and OS \[HR 0.39 (95% CI 0.18, 0.81); p = 0.007\] on multivariable analysis in patients who received more than 2 doses of anti-PD-1 therapies \[[@B12]\]. Quach et al. reviewed single institution data of 318 patients treated with anti-PD-1 therapies with or without ipilimumab and reported a better response rate (60.0% vs. 28.6%; *χ*^2^*p* \< .001), median PFS (797 vs. 112 days; log rank p \< .001), and median OS (1691 vs. 526 days; p\< .001) in patients who experienced cutaneous side effects. Superior outcomes with regard to response rate, PFS, and OS were seen with vitiligo and rash as compared to pruritus \[[@B13]\].

In this study, we analyzed the impact on PFS and OS for patients who discontinued anti-PD-1 therapy due to irAEs. Complete response was seen in patients with irAEs from a wide spectrum and grade of toxicities including grade 2 and 3 diarrhea/colitis (2 patients), grade 3 rash (3 patients), grade 3 pancreatitis (1 patient), grade 2 nephritis (1 patient), and grade 2 hypothyroidism, low mood, mouth sores, and rash (1 patient). We found a durable clinical benefit in thirteen patients (81.2%) discontinuing PD-1 directed therapy due to irAEs; none of them progressed in more than one year and 6 (37.5%) in more than 2 years ([Figure 3](#fig3){ref-type="fig"}). The benefit was not seen in patients with an underlying autoimmune disease like myasthenia gravis or who are at a higher risk of developing it, like patient 4 with thymoma \[[@B14]\]. However, because of the small sample size, no definitive conclusion should be drawn; this finding needs to be explored further.

KEYNOTE-001 has reported durable complete remission after discontinuation of pembrolizumab in patients with complete remission \[[@B5]\]. However, we found durable benefit in patients with residual disease also. Though the mechanisms for this phenomenon are not clear, it is very much possible that PD-1 blockade may result in an adaptive memory immune response providing antitumor effect even after treatment cessation and translating as irAEs \[[@B15]--[@B17]\]. A similar study evaluated 19 patients with metastatic renal cell carcinoma who experienced an initial clinical response but after irAE discontinued PD-1/PD-L1 therapy. The median time on PD-1/PD-L1 therapy was 5.5 months; median TTP was 18.4 months and durable clinical benefit off treatment (TTP \> 6 months) was observed in 68.4% (n=13) patients \[[@B15]\].

Pollack et al. reported that metastatic melanoma patients who discontinued CTLA4/PD-1 blockade due to irAEs can be rechallenged with anti-PD-1 therapies. The study showed a relatively higher rate of recurrent or different irAEs on resumption of anti-PD-1 therapies. They concluded that this approach can be used in selected patients \[[@B18]\]. We also found that patients who had to discontinue pembrolizumab due to irAE were able to be treated again with pembrolizumab-based therapies with manageable toxicities in two of the three patients. Our study has similar limitations as most retrospective studies including selection bias, chances of errors during data entry and confounding.

In summary, we present outcomes of 16 patients with metastatic melanoma who discontinued anti-PD-1 therapies due to immune toxicities. To the best of our knowledge, it is the largest series to date of real-world patients. Its strength includes a long-term follow-up and comprehensive analysis of each case which can help generate multiple hypotheses in combination with other relevant studies. Our results show durable clinical benefit in patients who discontinue anti-PD-1 therapies after irAEs. However, this needs to be confirmed in larger cohorts. We also need more comprehensive preclinical and clinical studies to determine how individual patient variables, cancer and immune system, interact to cause irAEs in only a select few patients while sparing a majority. We also need to develop predictive and prognostic novel biomarkers for anti-PD-1 therapies and also for irAEs.
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###### 

Patient demographics and clinical profile at the time of starting anti-PD-1 therapy.

  Pt. No.   Age (years)   Gender   Mutational status                     Brain metastasis   Liver metastasis   Prior adjuvant therapy   Prior therapy for metastatic disease                                                                           Prior immune-related adverse event                                                           Radiation therapy within prior 3 months   Prior relevant history or autoimmune disease
  --------- ------------- -------- ------------------------------------- ------------------ ------------------ ------------------------ -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------
  1         63            Male     BRAF V600E                            Yes                No                 Interferon               Ipilimumab, stereotactic radiosurgery                                                                          Colitis                                                                                      Yes                                       None
                                                                                                                                                                                                                                                                                                                                                                                              
  2         61            Female   BRAF Negative                         No                 No                 Radiation                Ipilimumab                                                                                                     Colitis, rash                                                                                No                                        Lichen planopilaris
                                                                                                                                                                                                                                                                                                                                                                                              
  3         72            Female   BRAF Negative                         No                 No                 GM-CSF                   Ipilimumab                                                                                                     Colitis                                                                                      No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  4         81            Male     BRAF V600K, GNAQ, RAC1, POLD1, TERT   Yes                No                 No                       Radiation, craniotomy and tumor resection, stereotactic radiosurgery                                           NA                                                                                           Yes                                       Thymoma
                                                                                                                                                                                                                                                                                                                                                                                              
  5         64            Male     BRAF V600E                            No                 No                 Radiation                Ipilimumab with talimogene laherparepvec                                                                       None                                                                                         No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  6         59            Female   NRAS                                  Yes                No                 Interferon               Ipilimumab, craniotomy and tumor resection, radiation                                                          None                                                                                         Yes                                       None
                                                                                                                                                                                                                                                                                                                                                                                              
  7         66            Female   BRAF V600E                            No                 No                 No                       NA                                                                                                             NA                                                                                           No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  8         35            Male     BRAF V600E, PTEN, MET                 No                 No                 Interferon               Ipilimumab with interleukin-2, ipilimumab                                                                      Diarrhea, nausea, vomiting, hyperbilirubinemia, acute kidney injury, oliguria, tachycardia   No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  9         61            Male     TP53                                  No                 No                 No                       NA                                                                                                             NA                                                                                           No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  10        77            Male     KIT p.W557G                           Yes                No                 Radiation                Stereotactic radiosurgery                                                                                      NA                                                                                           Yes                                       None
                                                                                                                                                                                                                                                                                                                                                                                              
  11        65            Male     NRAS, TP53, KIT, SF3B1, CDK2NA        No                 No                 No                       NA                                                                                                             NA                                                                                           No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  12        67            Female   Not done                              No                 No                 No                       NA                                                                                                             NA                                                                                           No                                        None
                                                                                                                                                                                                                                                                                                                                                                                              
  13        78            Male     BRAF p.L597S                          No                 No                 No                       Carboplatin with paclitaxel                                                                                    NA                                                                                           No                                        No
                                                                                                                                                                                                                                                                                                                                                                                              
  14        64            Male     BRAF V600K                            No                 No                 Radiation, ipilimumab    NA                                                                                                             Rash                                                                                         No                                        No
                                                                                                                                                                                                                                                                                                                                                                                              
  15        47            Female   BRAF V600E                            No                 No                 Interferon               Vemurafenib with high dose interleukin-2, vemurafenib with decitabine, craniotomy, stereotactic radiosurgery   Rash, diarrhea                                                                               Yes                                       No
                                                                                                                                                                                                                                                                                                                                                                                              
  16        75            Male     BRAF negative                         No                 Yes                No                       NA                                                                                                             NA                                                                                           No                                        Myasthenia gravis

###### 

Details of the line of anti-PD-1 therapy, duration of treatment, survival, and subsequent treatment on progression.

  PN   Anti-PD-1 Therapy   Line of anti-PD-1 therapy   ECOG PS   Response   DOT (months)   PFS (months)   TPTD (months)   Overall Survival (months)   Subsequent therapy
  ---- ------------------- --------------------------- --------- ---------- -------------- -------------- --------------- --------------------------- --------------------------------------------------------------------------------------------------
  1    Pembrolizumab       second                      1         PR         4.1            24.6           20.5            39.3*∗*                     Radiation, pembrolizumab with development of pembrolizumab induced psoriasis
                                                                                                                                                      
  2    Pembrolizumab       second                      0         CR         4.6            20.2           15.6            49.0*∗*                     Radiation, pembrolizumab with TLR9 agonist without immune toxicities
                                                                                                                                                      
  3    Nivolumab           second                      1         CR         2.6            49.4^+^        46.8^+^         49.4*∗*                     NA
                                                                                                                                                      
  4    Pembrolizumab       first                       1         SD         2.3            3.0            0.7             4.6                         Dabrafenib with trametinib
                                                                                                                                                      
  5    Pembrolizumab       second                      0         PR         3.5            30.3^+^        26.9^+^         30.3*∗*                     NA
                                                                                                                                                      
  6    Pembrolizumab       second                      1         CR         11.5           36.3^+^        24.8^+^         36.3*∗*                     NA
                                                                                                                                                      
  7    Pembrolizumab       first                       1         PR         4.8            18.1           13.3            23.4                        Radiation
                                                                                                                                                      
  8    Pembrolizumab       second                      1         SD         4.8            7.3            2.6             28.3*∗*                     Craniotomy and surgical resection, stereotactic radiosurgery, vemurafenib with cobimetinib
                                                                                                                                                      
  9    Pembrolizumab       first                       0         CR         6.5            17.5^+^        11.0^+^         17.5*∗*                     NA
                                                                                                                                                      
  10   Pembrolizumab       first                       1         CR         6.9            21.9^+^        15.0^+^         21.9*∗*                     NA
                                                                                                                                                      
  11   Pembrolizumab       first                       0         CR         9.7            30.1^+^        20.5^+^         30.1*∗*                     NA
                                                                                                                                                      
  12   Pembrolizumab       first                       0         CR         0.7            23.0^+^        22.3^+^         23.0*∗*                     NA
                                                                                                                                                      
  13   Pembrolizumab       second                      2         PR         4.6            16.8           12.2            25.0*∗*                     Radiation, dabrafenib with trametinib
                                                                                                                                                      
  14   Pembrolizumab       first                       0         PR         5.0            19.3           14.3            31.8                        Pembrolizumab with TLR9 agonist without immune toxicity, radiation, vemurafenib with cobimetinib
                                                                                                                                                      
  15   Pembrolizumab       third                       1         CR         11.5           37.3^+^        25.8^+^         37.3*∗*                     NA
                                                                                                                                                      
  16   Pembrolizumab       first                       0         PD         1.3            1.6            0.2             5.4                         Temozolomide

PN: patient number. ECOG PS: Eastern Cooperative Oncology Group Performance Status.

PR: partial response. CR: complete response. *∗*Alive.

SD: stable disease. PD: progressive disease. ^+-^Censored, no evidence of progression.

DOT: Duration of treatment.

TPTD: time to progression from treatment discontinuation.

###### 

Details of immune-related adverse events leading to discontinuation of anti-PD-1 therapy and their treatment.

  Patient Number                     irAE leading to discontinuation of anti-PD-1 therapy   Time of first presentation of any grade irAE from initiation of therapy (months)   Immune suppressive agents for treatment of irAE
  ---------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  1                                  Grade 2 inflammatory arthritis and neuropathy          4.1                                                                                Prednisone
                                                                                                                                                                               
  2                                  Grade 2 diarrhea                                       4                                                                                  Budesonide
                                                                                                                                                                               
  3                                  Grade 3 colitis and diarrhea                           2.6                                                                                Prednisone, budesonide
  Grade 2 adrenal insufficiency      4.1                                                    Hydrocortisone                                                                     
                                                                                                                                                                               
  4                                  Grade 3 sensorimotor polyneuropathy                    2.3                                                                                Prednisone
                                                                                                                                                                               
  5                                  Grade 1 diarrhea                                       2.8                                                                                Budesonide
  Grade 3 pancreatitis and colitis   3.5                                                    Budesonide                                                                         
                                                                                                                                                                               
  6                                  Grade 3 rash                                           11.5                                                                               Dexamethasone, topical steroids
                                                                                                                                                                               
  7                                  Grade 2 inflammatory arthritis                         4.6                                                                                Prednisone, methotrexate
                                                                                                                                                                               
  8                                  Grade 2 fatigue, nausea, diarrhea, arthritis           4.8                                                                                None
                                                                                                                                                                               
  9                                  Grade 3 pancreatitis                                   6.5                                                                                Prednisone
                                                                                                                                                                               
  10                                 Grade 2 nephritis                                      6.9                                                                                Prednisone
                                                                                                                                                                               
  11                                 Grade 2 hypothyroidism, low mood, mouth sores, rash    9.7                                                                                Topical steroids
                                                                                                                                                                               
  12                                 Grade 3 rash                                           0.5                                                                                Prednisone
                                                                                                                                                                               
  13                                 Grade 3 hepatitis                                      2.1                                                                                Prednisone, budesonide
                                                                                                                                                                               
  14                                 Grade 3 uveitis                                        3.9                                                                                Prednisone, ophthalmic prednisolone
                                                                                                                                                                               
  15                                 Grade 3 rash                                           11.3                                                                               Prednisone, topical steroids
                                                                                                                                                                               
  16                                 Grade 4 myasthenia flare                               0.8                                                                                Plasma exchange, mycophenolate mofetil, prednisone, intravenous immunoglobulin, abatacept

IrAE: immune-related adverse events.
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